RxDoctor Payments Data

Chelsea Cervellera

Nurse Practitioner · Ocala, FLNPI 1114379815

Payments from drug & device makers

$8,328in general payments, 2019–2025

Across 416 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biogen$601
  • Sanofi$539
  • UCB, Inc.$397
  • Novartis$397
  • Otsuka America Pharmaceutical, Inc.$355
  • plus $5K from 46 others

What the payments were for

  • Speaking & faculty fees$691%
  • Food & beverage$8,10497%
  • Education$1552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,328 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$39,991
Medicare patients
258
Services billed
303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnspryngSatralizumab-Mwge12$192,799
CopaxoneGlatiramer Acetate13$76,195
NuplazidPimavanserin Tartrate12$57,348
UbrelvyUbrogepant23$52,476
Emgality PenGalcanezumab-Gnlm33$43,087
Aimovig AutoinjectorErenumab-Aooe16$16,786
Pyridostigmine Bromide24$9,812
Levetiracetam210$9,776
Memantine Hcl220$9,684
Gabapentin290$6,598
Carbidopa-LevodopaCarbidopa/Levodopa163$5,870
Dalfampridine ErDalfampridine25$5,417
Duloxetine Hcl138$5,204
Primidone188$4,776
Piroxicam30$4,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Enspryng$207$192,79912 claims
Teva Pharmaceuticals USA, Inc.Copaxone$246$76,19513 claims
Acadia Pharmaceuticals IncNuplazid$170$57,34812 claims
AbbVieUbrelvy$1,492$52,47623 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$137$9,81224 claims
Almatica Pharma LLCSertraline Hcl$20$1,663119 claims
Upsher-smith Laboratories LLCTopiramate$52$1,26868 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →